Simvastatin Reduces Cancerogenic Potential of Renal Cancer Cells via Geranylgeranyl Pyrophosphate and Mevalonate Pathway

References

• Siegel R, Ma J, Zou, Z, and Jemal, A: Cancer statistics. CA Cancer J Clin 64, 9–29, 2014.
   PubMed Web of Science ®Google Scholar
• Gancaglia G, Ravi P, Abdollah F, Abd-El-Barr AM, Becker A, et al.: Contemporary incidence and mortality rates of kidney cancer in the United States. Can Urol Assoc J 8, 247–252, 2014.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, et al.: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67, 913–924, 2015.
   PubMed Web of Science ®Google Scholar
• Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS: Renal cell carcinoma 2005: new frontierts in staging, prognostication and targeted molecular therapy. J Urol 173, 1853–1862, 2005.
   PubMed Web of Science ®Google Scholar
• Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, et al.: Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmgenomics Pers Med 7, 107–116, 2014.
   PubMedGoogle Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R, et al.: MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 36, 2005–2016, 2003.
   Google Scholar
• Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22, 2002.
   PubMed Web of Science ®Google Scholar
• Osmak M: Statins and cancer: current and future prospects. Cancer Lett 324, 1–12, 2012.
   PubMed Web of Science ®Google Scholar
• Sassano A, Platanias LC: Statins in tumor suppression. Cancer Lett 260, 11–19, 2008.
   PubMed Web of Science ®Google Scholar
• Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J: Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 90, 9–17, 2008.
   PubMed Web of Science ®Google Scholar
• Gopalan A, Yu W, Sanders BG, Kline K: Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett 329, 9–16, 2013.
   PubMed Web of Science ®Google Scholar
• Hoque A, Chen H, Xu XC: Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 17, 88–94, 2008.
   PubMed Web of Science ®Google Scholar
• Kim YS, Seol C-H, Jung J-W, Oh S-J, Hwang K-E, et al.: Synergistic Effect of Sulindac and Simvastatin on Apoptosis in Lung Cancer A549 Cells through AKT-Dependent Downregulation of Survivin. Cancer Res Treat 47, 90–100, 2015.
   PubMed Web of Science ®Google Scholar
• Klawitter J, Shokati T, Moll V, Christians U, Klawitter J: Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res 12, R16, 2010.
   PubMed Web of Science ®Google Scholar
• Relja B, Meder F, Wang M, Blaheta R, Henrich D, et al.: Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol 38, 879–885.
   PubMed Web of Science ®Google Scholar
• Borahay MA, Kilic GS, Yallampalli C, Snyder RR, Hankins GD, et al.: Simvastatin potently induces calcium-dependent apoptosis of human leiomyoma cells. J Biol Chem 289, 35075–35086, 2014.
   PubMed Web of Science ®Google Scholar
• Huang X, Ma, J, Xu J, Su Q, Zhao J: Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Mol Med Rep 11, 2334–2340, 2014.
   PubMed Web of Science ®Google Scholar
• Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, et al.: Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res 30, 74, 2011.
   PubMed Web of Science ®Google Scholar
• Gallelli L, Falcone D, Scaramuzzino M, Pelaia G, D'Agostino B, et al.: Effects of simvastatin on cell viability and proinflammatory pathways in lung adenocarcinoma cells exposed to hydrogen peroxide. BMC Pharmacol Toxicol 15, 67, 2014.
   PubMed Web of Science ®Google Scholar
• Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, et al.: Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med 26, 735–741, 2010.
   PubMed Web of Science ®Google Scholar
• Relja B, Schwestka B, Lee VS, Henrich D, Czerny C, et al.: Inhibition of c-Jun N-terminal kinase after hemorrhage but before resuscitation mitigates hepatic damage and inflammatory response in male rats. Shock 32, 509–516, 2009.
   PubMed Web of Science ®Google Scholar
• Warita K, Warita T, Beckwitt CH, Schurdak ME, Vazquez A, et al.: Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci Rep 4, 7593, 2014.
   PubMed Web of Science ®Google Scholar
• Huang C, Freter C: Lipid Metabolism, Apoptosis and Cancer Therapy. Int J Mol Sci 16, 924–949, 2015.
   PubMed Web of Science ®Google Scholar
• Markowska A, Pawalowska M, Lubin J, Markowska J: Signalling pathways in endometrial cancer. Contemp Oncol 18, 143–148, 2014.
   Google Scholar
• Reed SM, Quelle DE: p53 Acetylation: Regulation and Consequences. Cancers (Basel) 7, 30–69, 2014.
   PubMed Web of Science ®Google Scholar
• Ukomadu C, Dutta A: p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 278, 43586–43594, 2003.
   PubMed Web of Science ®Google Scholar
• Olson MF, Ashworth A, Hall A: An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science ( abstr) 269, 1270–1272.
   PubMed Web of Science ®Google Scholar
• Sebti SM, Hamilton AD: Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol Ther ( abstr) 74, 103–114, 1997.
   PubMed Web of Science ®Google Scholar
• Stark WW Jr, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, et al.: Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol ( abstr) 275, L55–63, 1998.
   PubMed Web of Science ®Google Scholar
• Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, et al.: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272, 14459–14464, 1997.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee I, Park C, Kang WK: Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem Biophys Res Commun 339, 748–754, 2006.
   PubMed Web of Science ®Google Scholar
• Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, et al.: Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 45, 487–498, 2012.
   PubMed Web of Science ®Google Scholar
• Voelkel-Johnson C: TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol 8, 417–427, 2011.
   PubMed Web of Science ®Google Scholar
• Soldani C, Scovassi Al: Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7, 321–328, 2002.
   PubMed Web of Science ®Google Scholar
• Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, et al.: Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway. PLoS ONE 8, e62823, 2013.
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Bokemeyer C: Chemotherapy for renal cell carcinoma. Anticancer Res 19, 1541–1543, 1999.
   PubMed Web of Science ®Google Scholar
• Kodach LL, Jacobs RJ, Voomeveld PW, Wildenberg ME, Verspaget HW, et al.: Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell ‘stemness’ via the bone morphogenetic protein pathway. Gut 60, 1544–1553, 2011.
   PubMed Web of Science ®Google Scholar